ArticleAging clinical and experimental research2025
The global burden of varicella and herpes zoster in adults aged 65 years and older: a comprehensive analysis based on the global burden of disease 2021.
Article in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Low-Level Light Therapy in Postherpetic Neuralgia: A Review of Mechanistic Insights and Clinical Implications.Cellular and molecular neurobiology · 2026Review
- Development and validation of a machine learning model for predicting postherpetic neuralgia risk.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe global population is aging at an accelerated rate. There is a lack of data on the burden of varicella and herpes zoster in adults aged 65 years and older.
objectiveThis study assesses the global burden of varicella and herpes zoster among adults aged 65 and older from 1992 to 2021.
methodsWe used Global Burden of Disease (GBD) 2021 to identify the number and rates of incidence and disability-adjusted life years (DALYs) of varicella and herpes zoster in adults aged 65 and older.
resultsFrom 1992 to 2021, The age-standardized incidence rate (ASIR) of varicella and herpes zoster increased among adults aged 65 years and older, while the age-standardized death rate (ASDR) decreased. There were differences in the burden of varicella-zoster among adults aged 65 years and older by among sexes, ages, and regions. The health inequalities analysis showed an improvement among countries.
conclusionFrom 1992 to 2021, the global burden of varicella zoster among adults aged 65 and older has changed significantly. The ASIR of varicella and herpes zoster increased, but ASDR decreased. Despite the notable advancement in health equity across countries, the burden persists disproportionately among populations in low-SDI regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.